# Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

> **NCT05230901** · PHASE3 · UNKNOWN · sponsor: **University Medical Center Goettingen** · enrollment: 300 (estimated)

## Conditions studied

- Aortic Stenosis, Severe

## Interventions

- **OTHER:** Standard of Care
- **DRUG:** Spironolactone 25mg
- **DRUG:** Dihydralazine

## Key facts

- **NCT ID:** NCT05230901
- **Lead sponsor:** University Medical Center Goettingen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-23
- **Primary completion:** 2025-06
- **Final completion:** 2026-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05230901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05230901, "Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05230901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*